Interestingly, doxorubicin, a chemotherapy agent that is the backbone of current Ewing sarcoma therapy, also decreased EWS/FLI protein and induced the EWS/FLI off gene expression signature, and rapamycin, an mTOR inhibitor previously reported to decrease EWS/FLI protein, induces an EWS/FLI off signature. The gene discussed is EWSR1; the disease is Ewing sarcoma.